Dexloxiglumide
Alternative Names: CR-2017Latest Information Update: 18 May 2020
Price :
$50 *
At a glance
- Originator Rottapharm
- Developer Forest Laboratories; Rottapharm Madaus
- Class Gastrokinetics; Irritable bowel syndrome therapies; Pentanoic acids; Small molecules
- Mechanism of Action Cholecystokinin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastro-oesophageal reflux; Irritable bowel syndrome; Non-ulcer dyspepsia
- Discontinued Sleep apnoea syndrome
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 15 Oct 2015 Discontinued - Phase-II for Sleep apnoea syndrome (Treatment-naive) in Italy (PO)
- 04 Aug 2015 Phase III development for Irritable bowel syndrome, Gastro-oesophageal reflux and Non-ulcer dyspepsia is ongoing in Europe